Tilray   Report issue

For profit Phase 2 Phase 3
Founded: Nanaimo BC Canada (2013)
Status: No NME R&D (2013)

Organization Overview

First Clinical Trial
2016
NCT02517424
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Tilray

Active Ingredients

Drugs in Phase 3 Trials (2)

cannabidiol (Epidiolex) (4 trials)

sunflower oil (1 trial)

Drugs in Phase 2 Trials (3)

cannabis (1 trial)

temozolomide (temodar) (1 trial)

tetrahydrocannabinol (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Agoraphobia (Phase 3)

Anxiety Disorders (Phase 3)

Disease (Phase 3)

Epilepsy (Phase 1)

Essential Tremor (Phase 2)

Glioblastoma (Phase 2)

HIV Infections (Phase 2)

Panic Disorder (Phase 3)

Phobia, Social (Phase 3)

Stress Disorders, Post-Traumatic (Phase 2)

Stress Disorders, Traumatic (Phase 2)

Tremor (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 5